ESTA
Establishment Labs·NASDAQ
--
--(--)
--
--(--)
ESTA fundamentals
Establishment Labs (ESTA) released its earnings on Feb 24, 2026: revenue was 64.62M (YoY +45.16%), beat estimates; EPS was -0.09 (YoY +92.44%), beat estimates.
Revenue / YoY
64.62M
+45.16%
EPS / YoY
-0.09
+92.44%
Report date
Feb 24, 2026
ESTA Earnings Call Summary for Q4,2025
- Revenue Growth: Q4 2025 revenue up 45.2% YoY to $64.6 million, driven by U.S. Motiva implants and global minimally invasive procedures.
- Profitability: 70.5% gross margin, $5.5 million adjusted EBITDA (vs. -$13.1 million YoY), and $75.6 million cash balance.
- 2026 Outlook: $264-266 million revenue (25%+ growth), U.S. sales >30%, and free cash flow positive.
- Minimally Invasive Momentum: Preserve ASP 2x traditional augmentation, 15% of U.S. patients new to procedure, and $30+ million global portfolio.
- Reconstruction Expansion: FDA approval expected for 2027, targeting 200+ hospitals with Flora expanders.
- Global Leadership: 20%+ direct market growth, 700+ Preserve accounts, and 200+ trained surgeons.
EPS
Actual | -0.79 | -0.45 | -0.18 | -0.21 | -0.29 | -0.22 | -0.61 | -0.59 | -0.24 | -1.52 | -0.76 | -0.55 | -0.48 | -0.65 | -1.12 | -0.79 | -0.58 | -0.62 | -0.59 | -1.19 | -0.7 | -0.57 | -0.38 | -0.09 | |||||||
Forecast | -0.315 | -0.4532 | -0.3437 | -0.1887 | -0.3403 | -0.2805 | -0.3645 | -0.3324 | -0.3837 | -0.3985 | -0.5696 | -0.6784 | -0.6798 | -0.7156 | -0.8018 | -0.9121 | -0.6679 | -0.5131 | -0.615 | -0.6387 | -0.8072 | -0.5324 | -0.506 | -0.2221 | |||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -150.79% | +0.71% | +47.63% | -11.29% | +14.78% | +21.57% | -67.35% | -77.50% | +37.45% | -281.43% | -33.43% | +18.93% | +29.39% | +9.17% | -39.69% | +13.39% | +13.16% | -20.83% | +4.07% | -86.32% | +13.28% | -7.06% | +24.90% | +59.48% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | 24.50M | 10.47M | 22.76M | 27.00M | 30.34M | 31.99M | 29.04M | 35.30M | 38.45M | 41.19M | 38.20M | 43.81M | 46.52M | 48.56M | 38.51M | 31.56M | 37.20M | 44.12M | 40.23M | 44.51M | 41.38M | 51.30M | 53.78M | 64.62M |
Forecast | -- | -- | -- | -- | -- | -- | -- | 23.38M | 12.50M | 19.67M | 25.27M | 25.31M | 29.79M | 27.97M | 34.85M | 35.25M | 38.39M | 37.32M | 43.26M | 45.45M | 47.36M | 40.48M | 31.44M | 35.61M | 43.10M | 40.45M | 44.46M | 41.03M | 50.96M | 52.20M | 63.83M |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +4.78% | -16.19% | +15.68% | +6.85% | +19.88% | +7.41% | +3.82% | +1.28% | +9.08% | +7.28% | +2.35% | +1.28% | +2.37% | +2.53% | -4.88% | +0.37% | +4.46% | +2.36% | -0.55% | +0.12% | +0.84% | +0.66% | +3.03% | +1.24% |
Earnings Call
You can ask Aime
What is the market's earnings forecast for Establishment Labs next quarter?What were the key takeaways from Establishment Labs’s earnings call?What guidance did Establishment Labs's management provide for the next earnings period?What factors drove the changes in Establishment Labs's revenue and profit?What does Establishment Labs do and what are its main business segments?What were the key takeaways from Establishment Labs's earnings call?What is Establishment Labs's gross profit margin?What is Establishment Labs's latest dividend and current dividend yield?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
